Evidence map›Paper›PMID 35543677›Full record

ArticleBlood transfusion = Trasfusione del sangue2023

Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin

Emna Gouider, Anna Klukowska, Philip Maes, Helen Platokouki, Sonia Pujol, Céline Henriet, Françoise Bridey, Jenny Goudemand

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood transfusion = Trasfusione del sangue, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 0 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Emna GouiderHaemophilia Centre, Aziza Othmana Hospital, University Tunis El Manar, Tunis, Tunisia.
Anna KlukowskaDepartment of Oncology, Paediatric Haematology, Clinical Transplantology and Paediatrics of Warsaw Medical University, Warsaw, Poland.
Philip MaesUniversity Hospital of Antwerp, Paediatric Haematology and Oncology Department, Antwerp, Belgium.
Helen PlatokoukiHaemophilia-Centre-Haemostasis Unit, Aghia Sophia Children's Hospital, Athens, Greece.
Sonia PujolClinical Development, Laboratoire Français du Fractionnement et des Biotechnologies (LFB), Les Ulis, France.
Céline HenrietClinical Development, Laboratoire Français du Fractionnement et des Biotechnologies (LFB), Les Ulis, France.
Françoise BrideyFormerly Clinical Development, Laboratoire Français du Fractionnement et des Biotechnologies (LFB), Les Ulis, France.
Jenny GoudemandDepartment of Haemostasis and Transfusion, Lille University Hospital, Lille, France.
LFB (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlasma-derived von Willebrand factor (VWF) (Wilfactin MATERIAL AND

methodsPatients aged <6 years with severe VWD were enrolled in a multinational, open-label study to evaluate the in vivo recovery for Wilfactin

resultsNine patients, including 7 with type 3 VWD were exposed to treatment with Wilfactin DISCUSSION: The results show that Wilfactin

Indexed as

AnaphylaxisHemostaticsvon Willebrand DiseasesAdolescentAdultChildFactor VIIIHemorrhageHumansvon Willebrand FactorFactor VIIIHemostaticsvon Willebrand Factor

Identifiers

PMID35543677
PMCPMC9918383
OpenAlexW4280517851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.